for head and neck. Pembro shows 69% 1-year survival in advanced melanoma, nivo/combo comparisons remain difficult. Today Merck presented data from KEYNOTE-001, a very large phase lb study in which pembro showed a 69% I -year survival rate and an estimated 62% 18-month survival rate. One-year survival was